Page last updated: 2024-08-22

vidarabine and Anemia, Sickle Cell

vidarabine has been researched along with Anemia, Sickle Cell in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.25)18.7374
1990's1 (6.25)18.2507
2000's5 (31.25)29.6817
2010's8 (50.00)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Brochstein, J; Sahdev, I; Stiles, J; Werther, N1
Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S1
Bell, AD; Cheng, JC; Gutierrez, L; Karras, NA; Pawlowska, AB; Rosenthal, J; Sun, W; Wang, LD1
Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S1
Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Geyer, MB; Harrison, L; Jin, Z; Morris, E; Radhakrishnan, K1
Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Garvin, J; George, D; Geyer, MB; Hawks, R; Jin, Z; Lee, MT; Licursi, M; Morris, E; Radhakrishnan, K; Satwani, P; Schwartz, J; Smilow, E; Zuckerman, W1
Abraham, A; Benton, M; Brown, C; Chiang, KY; Dioguardi, JL; Grizzle, A; Haight, A; Hale, G; Horan, JT; Kanter, J; Kasow, KA; Nieder, M; Shelman, C1
Amylon, M; Casella, JF; Chen, AR; Fuchs, EJ; Iannone, R; Jones, RJ; Storb, RF; Sullivan, KM; Walters, MC; Woolfrey, A1
Blumberg, N; Fenton, P; Horan, JT; Liesveld, JL; Walters, MC1
Chao, N; Chute, J; Essell, J; Gasparetto, C; Horwitz, ME; Long, G; Morris, A; Rizzieri, D; Spasojevic, I; Sullivan, K; Telen, M1
Kim, HS; Niihara, Y; Yospur, L1
Bartholomew, A; Chen, YH; Devine, S; Hoffman, R; Koshy, M; Peace, D; Sher, D; Sosman, J; Stock, W; van Besien, K1
Kolb, HJ; Ledderose, G; Schlemmer, M; Schleuning, M; Stoetzer, O; Waterhouse, C1
Cox, F; Hughes, WT; Meyer, D1

Trials

7 trial(s) available for vidarabine and Anemia, Sickle Cell

ArticleYear
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
    Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:8

    Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prognosis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9

    Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2017
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine

2014
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
    Bone marrow transplantation, 2014, Volume: 49, Issue:7

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Prospective Studies; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult

2014
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5

    Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2015
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:8

    Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft Survival; Hematopoiesis; Humans; Immunocompetence; Kinetics; Male; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Bone marrow transplantation, 2005, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Combined Modality Therapy; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunosuppressive Agents; Infections; Male; Pancytopenia; Thalassemia; Transfusion Reaction; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2005

Other Studies

9 other study(ies) available for vidarabine and Anemia, Sickle Cell

ArticleYear
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:1

    Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine; Young Adult

2018
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2018
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
    Bone marrow transplantation, 2018, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult

2018
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4

    Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Graft Rejection; Graft Survival; Humans; Infant; Male; Myeloablative Agonists; Transplantation Conditioning; Unrelated Donors; Vidarabine

2013
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:12

    Topics: Adult; Anemia, Sickle Cell; Directed Tissue Donation; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kidney Failure, Chronic; Male; Myeloablative Agonists; Siblings; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
    The Western journal of medicine, 1998, Volume: 169, Issue:2

    Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1998
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
    Bone marrow transplantation, 2000, Volume: 26, Issue:4

    Topics: Adult; Anemia, Sickle Cell; Fatal Outcome; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2000
Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease.
    Experimental hematology, 2002, Volume: 30, Issue:1

    Topics: Adult; Anemia, Sickle Cell; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Cytomegalovirus in tears from patients with normal eyes and with acute cytomegalovirus chorioretinitis.
    American journal of ophthalmology, 1975, Volume: 80, Issue:5

    Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Chorioretinitis; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Idoxuridine; Immunosuppression Therapy; Infant; Leukemia, Lymphoid; Leukemia, Myeloid; Lupus Erythematosus, Systemic; Male; Tears; Vidarabine

1975